Similar articles for PMID: 29239232

Year	Number of Results
2006	3
2007	2
2008	1
2009	1
2010	3
2011	1
2012	2
2013	4
2014	10
2015	15
2016	16
2017	12
2018	8
2019	6
2020	3
2021	4
2022	4
2024	0

1

Effectiveness of Single- and Multiple-Tablet Antiretroviral Regimens in Correctional Setting for Treatment-Experienced HIV Patients.

Merker A, Badowski M, Chiampas T, Pérez SE, Patel M, Young J, Werner R. Merker A, et al. J Correct Health Care. 2018 Jan;24(1):52-61. doi: 10.1177/1078345817745334. Epub 2017 Dec 14. J Correct Health Care. 2018. PMID: 29239232

2

Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy.

Scott Sutton S, Magagnoli J, Hardin JW. Scott Sutton S, et al. Pharmacotherapy. 2016 Apr;36(4):385-401. doi: 10.1002/phar.1728. Epub 2016 Apr 13. Pharmacotherapy. 2016. PMID: 26923931

3

Odds of Viral Suppression by Single-Tablet Regimens, Multiple-Tablet Regimens, and Adherence Level in HIV/AIDS Patients Receiving Antiretroviral Therapy.

Sutton SS, Magagnoli J, Hardin JW. Sutton SS, et al. Pharmacotherapy. 2017 Feb;37(2):204-213. doi: 10.1002/phar.1889. Epub 2017 Feb 3. Pharmacotherapy. 2017. PMID: 28028855

4

Adherence among rural HIV-infected patients in the deep south: a comparison between single-tablet and multi-tablet once-daily regimens.

Tennant SJ, Hester EK, Caulder CR, Lu ZK, Bookstaver PB. Tennant SJ, et al. J Int Assoc Provid AIDS Care. 2015 Jan-Feb;14(1):64-71. doi: 10.1177/2325957414555228. Epub 2014 Oct 20. J Int Assoc Provid AIDS Care. 2015. PMID: 25331217 Free article.

5

Comparison of adherence to generic multi-tablet regimens vs. brand multi-tablet and brand single-tablet regimens likely to incorporate generic antiretroviral drugs by breaking or not fixed-dose combinations in HIV-infected patients.

Rwagitinywa J, Lapeyre-Mestre M, Bourrel R, Montastruc JL, Sommet A. Rwagitinywa J, et al. Fundam Clin Pharmacol. 2018 Aug;32(4):450-458. doi: 10.1111/fcp.12363. Epub 2018 Apr 23. Fundam Clin Pharmacol. 2018. PMID: 29505661

6

Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.

Wilkins EL, Cohen CJ, Trottier B, Esser S, Smith DE, Haas B, Brinson C, Garner W, Chuck S, Thorpe D, De-Oertel S. Wilkins EL, et al. AIDS Care. 2016;28(3):401-8. doi: 10.1080/09540121.2015.1096890. Epub 2015 Oct 21. AIDS Care. 2016. PMID: 26489045 Clinical Trial.

7

Single tablet HIV regimens facilitate virologic suppression and retention in care among treatment naïve patients.

Hemmige V, Flash CA, Carter J, Giordano TP, Zerai T. Hemmige V, et al. AIDS Care. 2018 Aug;30(8):1017-1024. doi: 10.1080/09540121.2018.1442554. Epub 2018 Feb 25. AIDS Care. 2018. PMID: 29478329 Free PMC article.

8

Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.

Arrabal-Durán P, Rodríguez-González CG, Chamorro-de-Vega E, Gijón-Vidaurreta P, Herranz-Alonso A, Sanjurjo-Sáez M. Arrabal-Durán P, et al. Int J Clin Pract. 2017 Aug;71(8). doi: 10.1111/ijcp.12968. Epub 2017 Jul 19. Int J Clin Pract. 2017. PMID: 28722790

9

Cost considerations in the current antiretroviral era.

Eaton EF, Tamhane A, Saag M, Mugavero MJ, Kilgore ML. Eaton EF, et al. AIDS. 2016 Sep 10;30(14):2115-9. doi: 10.1097/QAD.0000000000001120. AIDS. 2016. PMID: 27088319 Free PMC article.

10

Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).

Slama L, Landman R, Assoumou L, Benalycherif A, Samri A, Joly V, Pialoux G, Valin N, Cabié A, Duvivier C, Lambert-Niclot S, Marcelin AG, Peytavin G, Costagliola D, Girard PM; IMEA 040 DATA Study Group. Slama L, et al. J Antimicrob Chemother. 2016 Aug;71(8):2252-61. doi: 10.1093/jac/dkw103. Epub 2016 Apr 10. J Antimicrob Chemother. 2016. PMID: 27068399 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

81 results

Results by year